AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KJUN 112 min read$COGT

Cogent Biosciences, Inc. (COGT): Submission of Matters to a Vote of Security Holders

Cogent Biosciences, Inc. (COGT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001622229 0001622229 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 9, 2

Original reporting
SEC EDGAR 8-K
Published Jun 11, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$COGT
Neutral
high confidence
Mentioned
$COGT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$COGTNeutralLow
01

Why it matters

This is a procedural disclosure of election/ratification/advisory vote results; it does not introduce new business developments.

02

Market read

Primarily confirms governance continuity; limited trading relevance absent any new catalyst.

03

What to watch

Broker non-votes and withheld votes are disclosed, but the article does not indicate contested outcomes or governance changes that would typically drive repricing.

Relevance 6/10Novelty 2/10Timing: Filed June 11, 2026 for June 9 annual meeting vote results

Background

The company submitted voting results from its 2026 annual stockholders meeting via SEC Form 8-K (Item 5.07).

Company-level read

Ticker impact

$COGTNeutralHigh confidence
Context

Cogent Biosciences filed an 8-K confirming director nominees were elected and other proposals approved at its June 9, 2026 annual meeting.

Expected impact

Low likelihood of sustained price impact; any reaction would be limited to short-term sentiment around governance/management continuity.

Evidence & confidence

The filing reports election/ratification/advisory vote tallies without changes to guidance, trials, financing, or material transactions.

Market effects

Sector

None; governance vote results do not alter biotech sector fundamentals.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

If traders were positioned around potential board/compensation controversy, the vote outcome could reduce uncertainty, but the filing provides no new dispute or reversal.

Key entities

  • issuer
    Cogent Biosciences, Inc.

    Nasdaq-listed company reporting annual meeting voting outcomes.

  • director_nominee
    Chris Cain, Ph.D.

    Elected director nominee (votes for/withheld and broker non-votes reported).

  • director_nominee
    Arlene Morris

    Elected director nominee (votes for/withheld and broker non-votes reported).

  • director_nominee
    Todd Shegog

    Elected director nominee (votes for/withheld and broker non-votes reported).

Read at source← All news

Related articles

SEP 15
$COGTHighAI 8/10

Cogent's Bezuclastinib NDA Accepted For Advanced Systemic Mastocytosis; PDUFA Set For June 2027

Cogent Biosciences (COGT) announced FDA acceptance of its NDA for Bezuclastinib to treat Advanced Systemic Mastocytosis, with a PDUFA target date of June 2027. The NDA is supported by APEX trial data showing a 65% overall response rate and 79% 12-month progression-free survival. The FDA has not identified any review issues. COGT is also advancing NDAs for other indications. The stock is currently trading at $33.49, up 0.24%.

rttnews.com2 min
AUG 10
$COGTMed

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Cogent Biosciences, Inc. (COGT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Applicatio

SEC EDGAR 8-K6 min
OCT 24
$BPMed

bp to pay Louisiana $350M to settle remaining Deepwater Horizon claims

bp agreed to pay Louisiana $350M to settle remaining Deepwater Horizon claims, accelerating payments under the 2015 settlement. The payment resolves coastal zone litigation and provides Louisiana with earlier access to funds. bp CEO Meg O’Neill noted the agreement supports the state's investment and job creation. The 2015 settlement totaled up to $18.7B, with $4.9B allocated to Gulf Coast states.

trend.az2 min
OCT 24
$000660.KSMed

SK Hynix abandons plans for US listing

SK Hynix canceled plans for a $10 billion U.S. IPO of its Solidigm unit due to regulatory opposition and shareholder concerns, citing market conditions. The decision follows scrutiny over potential share dilution and ownership structure complexities. SK Hynix shares rose after the announcement, despite broader market declines. Solidigm, a major flash memory producer, had planned to list as soon as next year, aiming for a valuation of up to $100 billion.

arkansasonline.com2 min